HIV-1 tests approved
This article was originally published in The Gray Sheet
Executive Summary
Abbott's RealTime HIV-1 and Roche's Cobas AmpliPrep/Cobas TaqMan HIV-1 tests receive FDA PMA approval May 11. Both tests measure viral load of HIV-I Group M, including non-B subtypes through real-time PCR. The RealTime test is designed for use with Abbott's m2000 automated instrument system while the Roche test works with that firm's Cobas TaqMan automated analyzer. Abbott's m2000 system also is available in Europe, along with the firm's viral tests for HIV-1, hepatitis C, Chlamydia trachomatis (CT), and a combination test for CT/Neisseria gonorrhoeae. Roche notes that its hepatitis B and C tests, for use on the same Roche platform as the HIV-1 test, are under FDA review...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.